Restoring airway epithelial barrier dysfunction: A new therapeutic challenge in allergic airway disease

Rhinology

Volumn 54, Issue 3, 2016, Pages 195-205

  Steelant, Brecht ^a   Seys, Sven F ^a   Boeckxstaens, Guy ^a   Akdis, Cezmi A ^b   Ceuppens, Jan L ^a   Hellings, Peter W ^a,c,d,e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Allergic rhinitis; Chronic rhinosinusitis; EGF signaling; Fluticasone; Tight junctions; Trans epithelial electric resistance

Indexed keywords

ASTHMA; ATOPIC DERMATITIS; EPITHELIUM; GASTROINTESTINAL DISEASE; HUMAN; NOSE MUCOSA; PATHOPHYSIOLOGY; RESPIRATORY SYSTEM; RHINITIS; SINUSITIS;

ASTHMA; DERMATITIS, ATOPIC; EPITHELIUM; GASTROINTESTINAL DISEASES; HUMANS; NASAL MUCOSA; RESPIRATORY SYSTEM; RHINITIS; SINUSITIS;

EID: 84986879681     PISSN: 03000729     EISSN: 19968604     Source Type: Journal    
DOI: 10.4193/Rhino15.376     Document Type: Review

References (107)

1. Koch S, Nusrat A. The life and death of epithelia during inflammation: lessons learned from the gut. Annu Rev Pathol 2012; 7:35-60.
2. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23:327-33.
3. Parker D, Prince A. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 2011; 45:189-201.
4. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med 2012; 18:684-92.
5. Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004; 31:358-64.
6. Vroling AB, Fokkens WJ, van Drunen CM. How epithelial cells detect danger: aiding the immune response. Allergy 2008; 63:1110-23.
7. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol 2014; 134:509-20.
8. Shen L, Weber CR, Raleigh DR, Yu D, Turner JR. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 2011; 73:283-309.
9. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303:1483-7.
10. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008; 1778:660-9.
11. Brooke MA, Nitoiu D, Kelsell DP. Cell-cell connectivity: desmosomes and disease. J Pathol 2012; 226:158-71.
12. Niessen CM. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol 2007; 127:2525-32.
13. Johnson JL, Najor NA, Green K J. Desmosomes: regulators of cellular signaling and adhesion in epidermal health and disease. Cold Spring Harb Perspect Med 2014; 4:a015297.
14. Schulzke JD, Fromm M. Tight junctions: molecular structure meets function. Ann N Y Acad Sci 2009; 1165:1-6.
15. Rezaee F, Georas SN. Breaking barriers. New insights into airway epithelial barrier function in health and disease. Am J Respir Cell Mol Biol 2014; 50:857-69.
16. Gunzel D, Yu AS. Claudins and the modulation of tight junction permeability. Physiol Rev 2013; 93:525-69.
17. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006; 68:403-29.
18. Amasheh S, Meiri N, Gitter AH, Schoneberg T, Mankertz J, Schulzke JD, et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci 2002; 115:4969-76.
19. Alexandre MD, Lu Q, Chen YH. Overexpression of claudin-7 decreases the paracellular Cl-conductance and increases the paracellular Na+ conductance in LLC-PK1 cells. J Cell Sci 2005; 118:2683-93.
20. Inai T, Kobayashi J, Shibata Y. Claudin-1 contributes to the epithelial barrier function in MDCK cells. Eur J Cell Biol 1999; 78:849-55.
21. Hou J, Renigunta A, Yang J, Waldegger S. Claudin-4 forms paracellular chloride channel in the kidney and requires claudin-8 for tight junction localization. Proc Natl Acad Sci U S A 2010; 107:18010-5.
22. Utech M, Bruwer M, Nusrat A. Tight junctions and cell-cell interactions. Methods Mol Biol 2006; 341:185-95.
23. Mehta S, Nijhuis A, Kumagai T, Lindsay J, Silver A. Defects in the adherens junction complex (E-cadherin/ beta-catenin) in inflammatory bowel disease. Cell Tissue Res 2015; 360:749-60.
24. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011; 127:773-86 e1-7.
25. Schulzke JD, Ploeger S, Amasheh M, Fromm A, Zeissig S, Troeger H, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 2009; 1165:294-300.
26. Steelant B, Farre R, Wawrzyniak P, Belmans J, Dekimpe E, Vanheel H, et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol. 2016;137(4):1043-1053.
27. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004; 113:651-7.
28. Vickery BP. Skin barrier function in atopic dermatitis. Curr Opin Pediatr 2007; 19:89-93.
29. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003; 112:S118-27.
30. Madison KC. Barrier function of the skin: “la raison d’etre” of the epidermis. J Invest Dermatol 2003; 121:231-41.
31. Imokawa G. Lipid abnormalities in atopic dermatitis. J Am Acad Dermatol 2001; 45:S29-32.
32. Pilgram GS, Vissers DC, van der Meulen H, Pavel S, Lavrijsen SP, Bouwstra JA, et al. Aberrant lipid organization in stratum corneum of patients with atopic dermatitis and lamellar ichthyosis. J Invest Dermatol 2001; 117:710-7.
33. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441-6.
34. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999; 116:301-9.
35. Marin ML, Greenstein AJ, Geller SA, Gordon RE, Aufses AH, Jr. A freeze fracture study of Crohn’s disease of the terminal ileum: changes in epithelial tight junction organization. Am J Gastroenterol 1983; 78:537-47.
36. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 2007; 56:61-72.
37. Gitter AH, Wullstein F, Fromm M, Schulzke JD. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001; 121:1320-8.
38. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127:1239-55.
39. Vanheel H, Vicario M, Vanuytsel T, Van Oudenhove L, Martinez C, Keita AV, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 2014; 63:262-71.
40. de Boer WI, Sharma HS, Baelemans SM, Hoogsteden HC, Lambrecht BN, Braunstahl GJ. Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation. Can J Physiol Pharmacol 2008; 86:105-12.
41. Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011; 128:549-56 e1-12.
42. Losifidis T, Garratt LW, Coombe DR, Knight DA, Stick SM, Kicic A. Airway epithelial repair in health and disease: Orchestrator or simply a player? Respirology. 2016;21(3):438-48.
43. Davies DE. Epithelial barrier function and immunity in asthma. Ann Am Thorac Soc 2014; 11 Suppl 5:S244-51.
44. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-gamma and IL-4. J Allergy Clin Immunol 2012; 130:1087-96 e10.
45. Kast JI, Wanke K, Soyka MB, Wawrzyniak P, Akdis D, Kingo K, et al. The broad spectrum of interepithelial junctions in skin and lung. J Allergy Clin Immunol 2012; 130:544-7 e4.
46. Suenaert P, Maerten P, Van Assche G, Van Driessche W, Geboes K, Bulteel V, et al. Effects of T cell-induced colonic inflammation on epithelial barrier function. Inflamm Bowel Dis 2010; 16:1322-31.
47. Nicodemus-Johnson J, Naughton KA, Sudi J, Hogarth K, Naurekas ET, Nicolae DL, et al. Genome-Wide Methylation Study Identifies an IL-13-induced Epigenetic Signature in Asthmatic Airways. Am J Respir Crit Care Med 2016; 193:376-85.
48. Dimova S, Brewster ME, Noppe M, Jorissen M, Augustijns P. The use of human nasal in vitro cell systems during drug discovery and development. Toxicol In Vitro 2005; 19:107-22.
49. Bobic S, van Drunen CM, Callebaut I, Hox V, Jorissen M, Fokkens WJ, et al. Dexamethasone-induced apoptosis of freshly isolated human nasal epithelial cells concomitant with abrogation of IL-8 production. Rhinology 2010; 48:401-7.
50. Merkle HP, Ditzinger G, Lang SR, Peter H, Schmidt MC. In vitro cell models to study nasal mucosal permeability and metabolism. Adv Drug Deliv Rev 1998; 29:51-79.
51. De Fraissinette A, Brun R, Felix H, Vonderscher J, Rummelt A. Evaluation of the human cell line RPMI 2650 as an in vitro nasal model. Rhinology 1995; 33:194-8.
52. Shen BQ, Finkbeiner WE, Wine JJ, Mrsny RJ, Widdicombe JH. Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl-secretion. Am J Physiol 1994; 266:L493-501.
53. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994; 10:38-47.
54. Wallon C, Braaf Y, Wolving M, Olaison G, Soderholm JD. Endoscopic biopsies in Ussing chambers evaluated for studies of macromolecular permeability in the human colon. Scand J Gastroenterol 2005; 40:586-95.
55. Hox V, Vanoirbeek JA, Callebaut I, Bobic S, De Vooght V, Ceuppens J, et al. Airway exposure to hypochlorite prior to ovalbumin induces airway hyperreactivity without evidence for allergic sensitization. Toxicol Lett 2011; 204:101-7.
56. Hox V, Vanoirbeek JA, Alpizar YA, Voedisch S, Callebaut I, Bobic S, et al. Crucial role of transient receptor potential ankyrin 1 and mast cells in induction of nonallergic airway hyperreactivity in mice. Am J Respir Crit Care Med 2013; 187:486-93.
57. Wan H, Winton HL, Soeller C, Tovey ER, Gruenert DC, Thompson PJ, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 1999; 104:123-33.
58. Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J Clin Invest 2004; 113:1482-9.
59. Ragupathy S, Esmaeili F, Paschoud S, Sublet E, Citi S, Borchard G. Toll-like receptor 2 regulates the barrier function of human bronchial epithelial monolayers through atypical protein kinase C zeta, and an increase in expression of claudin-1. Tissue Barriers 2014; 2:e29166.
60. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8.
61. Ohkuni T, Kojima T, Ogasawara N, Masaki T, Fuchimoto J, Kamekura R, et al. Poly(I:C) reduces expression of JAM-A and induces secretion of IL-8 and TNF-alpha via distinct NF-kappaB pathways in human nasal epithelial cells. Toxicol Appl Pharmacol 2011; 250:29-38.
62. Miyata R, Kakuki T, Nomura K, Ohkuni T, Ogasawara N, Takano K, et al. Poly(I:C) induced microRNA-146a regulates epithelial barrier and secretion of proinflammatory cytokines in human nasal epithelial cells. Eur J Pharmacol 2015; 761:375-82.
63. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005; 310:1817-21.
64. Suojalehto H, Toskala E, Kilpelainen M, Majuri ML, Mitts C, Lindstrom I, et al. MicroRNA profiles in nasal mucosa of patients with allergic and nonallergic rhinitis and asthma. Int Forum Allergy Rhinol 2013; 3:612-20.
65. Ye D, Guo S, Al-Sadi R, Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology 2011; 141:1323-33.
66. Cichon C, Sabharwal H, Ruter C, Schmidt MA. MicroRNAs regulate tight junction proteins and modulate epithelial/endothelial barrier functions. Tissue Barriers 2014; 2:e944446.
67. Buggele WA, Johnson KE, Horvath CM. Influenza A virus infection of human respiratory cells induces primary microRNA expression. J Biol Chem 2012; 287:31027-40.
68. Kojima T, Go M, Takano K, Kurose M, Ohkuni T, Koizumi J, et al. Regulation of tight junctions in upper airway epithelium. Biomed Res Int 2013; 2013:947072.
69. Kubo T, Wawrzyniak P, Morita H, Sugita K, Wanke K, Kast JI, et al. CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier. J Allergy Clin Immunol 2015.
70. Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013; 131:866-74.
71. Robbesyn F, Garcia V, Auge N, Vieira O, Frisach MF, Salvayre R, et al. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 2003; 17:743-5.
72. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005; 15:158-61.
73. Yao X, Dai C, Fredriksson K, Dagur PK, McCoy JP, Qu X, et al. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J Immunol 2011; 186:576-83.
74. Park SW, Lee EH, Lee EJ, Kim HJ, Bae DJ, Han S, et al. Apolipoprotein A1 potentiates lipoxin A4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium. Clin Exp Allergy 2013; 43:914-27.
75. Bonnans C, Chanez P, Chavis C. Lipoxins in asthma: potential therapeutic mediators on bronchial inflammation? Allergy 2004; 59:1027-41.
76. Grumbach Y, Quynh NV, Chiron R, Urbach V. LXA4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial (16HBE14o-) cells. Am J Physiol Lung Cell Mol Physiol 2009; 296:L101-8.
77. Chen ML, Pothoulakis C, LaMont JT. Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J Biol Chem 2002; 277:4247-54.
78. Tillie-Leblond I, Gosset P, Le Berre R, Janin A, Prangere T, Tonnel AB, et al. Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic rats. Eur Respir J 2007; 30:31-9.
79. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265:7709-12.
80. Rao R, Baker RD, Baker SS. Inhibition of oxidant-induced barrier disruption and protein tyrosine phosphorylation in Caco-2 cell monolayers by epidermal growth factor. Biochem Pharmacol 1999; 57:685-95.
81. Basuroy S, Seth A, Elias B, Naren AP, Rao R. MAPK interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide. Biochem J 2006; 393:69-77.
82. Schamberger AC, Mise N, Jia J, Genoyer E, Yildirim AO, Meiners S, et al. Cigarette smoke-induced disruption of bronchial epithelial tight junctions is prevented by transforming growth factor-beta. Am J Respir Cell Mol Biol 2014; 50:1040-52.
83. Saatian B, Rezaee F, Desando S, Emo J, Chapman T, Knowlden S, et al. Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers 2013; 1:e24333.
84. Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol 2007; 120:1233-44; quiz 45-6.
85. Ying S, O’Connor B, Ratoff J, Meng Q, Mallett K, Cousins D, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005; 174:8183-90.
86. Kamekura R, Kojima T, Koizumi J, Ogasawara N, Kurose M, Go M, et al. Thymic stromal lymphopoietin enhances tight-junction barrier function of human nasal epithelial cells. Cell Tissue Res 2009; 338:283-93.
87. Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 2008; 121:5-10; quiz 1-2.
88. Babu SK, Puddicombe SM, Arshad HH, Wilson SJ, Ward J, Gozzard N, et al. Tumor necrosis factor alpha (TNF-alpha) autoregulates its expression and induces adhesion molecule expression in asthma. Clin Immunol 2011; 140:18-25.
89. Hardyman MA, Wilkinson E, Martin E, Jayasekera NP, Blume C, Swindle EJ, et al. TNF-alpha-mediated bronchial barrier disruption and regulation by src-family kinase activation. J Allergy Clin Immunol 2013; 132:665-75 e8.
90. Dorfel MJ, Huber O. Modulation of tight junction structure and function by kinases and phosphatases targeting occludin. J Biomed Biotechnol 2012; 2012:807356.
91. Huang S, Dudez T, Scerri I, Thomas MA, Giepmans BN, Suter S, et al. Defective activation of c-Src in cystic fibrosis airway epithelial cells results in loss of tumor necrosis factor-alpha-induced gap junction regulation. J Biol Chem 2003; 278:8326-32.
92. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet 2011; 378:2112-22.
93. Schleimer RP. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990; 141:S59-69.
94. Schwiebert LM, Beck LA, Stellato C, Bickel CA, Bochner BS, Schleimer RP. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol 1996; 97:143-52.
95. Wild GE, Waschke KA, Bitton A, Thomson AB. The mechanisms of prednisone inhibition of inflammation in Crohn’s disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther 2003; 18:309-17.
96. Fischer A, Gluth M, Weege F, Pape UF, Wiedenmann B, Baumgart DC, et al. Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol 2014; 306:G218-28.
97. Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY. Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2007; 292:G590-8.
98. Sekiyama A, Gon Y, Terakado M, Takeshita I, Kozu Y, Maruoka S, et al. Glucocorticoids enhance airway epithelial barrier integrity. Int Immunopharmacol 2012; 12:350-7.
99. Wancket LM, Frazier WJ, Liu Y. Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci 2012; 90:237-48.
100. Ma TY, Boivin MA, Ye D, Pedram A, Said HM. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005; 288:G422-30.
101. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004; 286:G367-76.
102. Hox V, Steelant B, Fokkens W, Nemery B, Hellings PW. Occupational upper airway disease: how work affects the nose. Allergy 2014; 69:282-91.
103. Cornelis M, Rombaux P, Jorissen M, Hellings PW. Nationwide survey on immunotherapy practice by ENT specialists. Rhinology 2014; 52:72-7.
104. Petalas K, Durham SR. Allergen immunotherapy for allergic rhinitis. Rhinology 2013; 51:99-110.
105. Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol 2010; 126:666-8 e1-5.
106. Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013; 68:1-7.
107. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol 2013; 11:1075-83.